ArticleEuropean journal of hospital pharmacy : science and practice2019

Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience.

Jan Miroslav Hartinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.